OBJECTIVE: Systemic lupus erythematosus (SLE) is more prevalent and results in more severe outcomes among blacks, Asians, and Hispanics than among whites. Cardiovascular disease (CVD) is the leading cause of death among SLE patients. We undertook this study to examine racial/ethnic variations in risk of CVD events among SLE patients. METHODS: Within the Medicaid Analytic eXtract from 2000 to 2010, we identified patients ages 18-65 years with SLE (≥3 International Classification of Diseases, Ninth Revision 710.0 codes, ≥30 days apart) and with ≥12 months of continuous enrollment. Subjects were followed up from the index date to the first CVD event (myocardial infarction [MI] or stroke), death, disenrollment, loss to follow-up, or end of follow-up period. Race/ethnicity-specific annual CVD event rates were calculated. Cox regression models estimated hazard ratios (HRs) with 95% confidence intervals (95% CIs), accounting for competing risk of death and adjusting for baseline demographics and comorbidities. RESULTS: Of 65,788 SLE patients, 93.1% were women and ∼42% were black, 38% were white, 16% were Hispanic, 3% were Asian, and 1% were American Indian/Alaska Native. Mean ± SD follow-up was 3.8 ± 3.1 years. CVD event rates were highest among blacks (incidence rate [IR] 10.57 [95% CI 9.96-11.22]) and lowest among Asians (IR 6.63 [95% CI 4.97-8.85]). After multivariable adjustment, risk of CVD events was increased among blacks (HR 1.14 [95% CI 1.03-1.26]) compared to whites. Hispanics and Asians had a lower risk of MI (HR 0.61 [95% CI 0.48-0.77] and HR 0.57 [95% CI 0.34-0.96], respectively), while blacks and Hispanics had a higher risk of stroke (HR 1.31 [95% CI 1.15-1.49] and HR 1.22 [95% CI 1.03-1.44], respectively). CONCLUSION: Among SLE patients enrolled in Medicaid, the risk of MI was lower among Hispanics and Asians compared to whites, while the risk of stroke was elevated among blacks and Hispanics compared to whites.
OBJECTIVE:Systemic lupus erythematosus (SLE) is more prevalent and results in more severe outcomes among blacks, Asians, and Hispanics than among whites. Cardiovascular disease (CVD) is the leading cause of death among SLEpatients. We undertook this study to examine racial/ethnic variations in risk of CVD events among SLEpatients. METHODS: Within the Medicaid Analytic eXtract from 2000 to 2010, we identified patients ages 18-65 years with SLE (≥3 International Classification of Diseases, Ninth Revision 710.0 codes, ≥30 days apart) and with ≥12 months of continuous enrollment. Subjects were followed up from the index date to the first CVD event (myocardial infarction [MI] or stroke), death, disenrollment, loss to follow-up, or end of follow-up period. Race/ethnicity-specific annual CVD event rates were calculated. Cox regression models estimated hazard ratios (HRs) with 95% confidence intervals (95% CIs), accounting for competing risk of death and adjusting for baseline demographics and comorbidities. RESULTS: Of 65,788 SLEpatients, 93.1% were women and ∼42% were black, 38% were white, 16% were Hispanic, 3% were Asian, and 1% were American Indian/Alaska Native. Mean ± SD follow-up was 3.8 ± 3.1 years. CVD event rates were highest among blacks (incidence rate [IR] 10.57 [95% CI 9.96-11.22]) and lowest among Asians (IR 6.63 [95% CI 4.97-8.85]). After multivariable adjustment, risk of CVD events was increased among blacks (HR 1.14 [95% CI 1.03-1.26]) compared to whites. Hispanics and Asians had a lower risk of MI (HR 0.61 [95% CI 0.48-0.77] and HR 0.57 [95% CI 0.34-0.96], respectively), while blacks and Hispanics had a higher risk of stroke (HR 1.31 [95% CI 1.15-1.49] and HR 1.22 [95% CI 1.03-1.44], respectively). CONCLUSION: Among SLEpatients enrolled in Medicaid, the risk of MI was lower among Hispanics and Asians compared to whites, while the risk of stroke was elevated among blacks and Hispanics compared to whites.
Authors: Salvador Cruz-Flores; Alejandro Rabinstein; Jose Biller; Mitchell S V Elkind; Patrick Griffith; Philip B Gorelick; George Howard; Enrique C Leira; Lewis B Morgenstern; Bruce Ovbiagele; Eric Peterson; Wayne Rosamond; Brian Trimble; Amy L Valderrama Journal: Stroke Date: 2011-05-26 Impact factor: 7.914
Authors: G S Cooper; C G Parks; E L Treadwell; E W St Clair; G S Gilkeson; P L Cohen; R A S Roubey; M A Dooley Journal: Lupus Date: 2002 Impact factor: 2.911
Authors: Carlos J Rodriguez; Matthew Allison; Martha L Daviglus; Carmen R Isasi; Colleen Keller; Enrique C Leira; Latha Palaniappan; Ileana L Piña; Sarah M Ramirez; Beatriz Rodriguez; Mario Sims Journal: Circulation Date: 2014-07-14 Impact factor: 29.690
Authors: Candace H Feldman; Linda T Hiraki; Jun Liu; Michael A Fischer; Daniel H Solomon; Graciela S Alarcón; Wolfgang C Winkelmayer; Karen H Costenbader Journal: Arthritis Rheum Date: 2013-03
Authors: Bruce M Psaty; Joseph A Delaney; Alice M Arnold; Lesley H Curtis; Annette L Fitzpatrick; Susan R Heckbert; Barbara McKnight; Diane Ives; John S Gottdiener; Lewis H Kuller; W T Longstreth Journal: Circulation Date: 2015-11-04 Impact factor: 29.690
Authors: José A Gómez-Puerta; Sushrut S Waikar; Daniel H Solomon; Jun Liu; Graciela S Alarcón; Wolfgang C Winkelmayer; Karen H Costenbader Journal: J Clin Cell Immunol Date: 2013-12-01
Authors: Sara K Tedeschi; Seoyoung C Kim; Hongshu Guan; Jennifer M Grossman; Karen H Costenbader Journal: Arthritis Rheumatol Date: 2019-06-05 Impact factor: 10.995
Authors: Medha Barbhaiya; Candace H Feldman; Hongshu Guan; Sarah K Chen; Michael A Fischer; Daniel H Solomon; Brendan M Everett; Karen H Costenbader Journal: Semin Arthritis Rheum Date: 2018-07-31 Impact factor: 5.532
Authors: Candace H Feldman; Cameron Speyer; Rachel Ashby; Bonnie L Bermas; Shamik Bhattacharyya; Eliza Chakravarty; Brendan Everett; Elizabeth Ferucci; Aimee O Hersh; Francisco M Marty; Joseph F Merola; Rosalind Ramsey-Goldman; Brad H Rovin; Mary Beth Son; Laura Tarter; Sushrut Waikar; Jinoos Yazdany; Joel S Weissman; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2021-01 Impact factor: 4.794
Authors: May Y Choi; Daniel Li; Candace H Feldman; Kazuki Yoshida; Hongshu Guan; Seoyoung C Kim; Brendan M Everett; Karen H Costenbader Journal: Rheumatology (Oxford) Date: 2021-08-02 Impact factor: 7.580